Shin Nippon Biomedical Laboratories Ltd

Research Shin Nippon Biomedical Laboratories Ltd (YB3) on Bullrun: valuation model: 19.4% undervalued, market cap EUR 253.95M, P/E 10.2, dividend yield 4.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerYB3
• ExchangeF
• CountryJapan
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyEUR
• Valuation signal19.4% undervalued
• Market capEUR 253.95M
• P/E10.2
• Dividend yield4.5%
• Financial periodFY2025
• RevenueEUR 32.41B
• Revenue growth22.5%
• Net incomeEUR 4.92B
• Free cash flow-EUR 3.90B
• Gross margin52.3%

Valuation Snapshot

Bullrun's latest valuation model marks Shin Nippon Biomedical Laboratories Ltd as 19.4% undervalued; latest market cap is EUR 253.95M; P/E is 10.2; dividend yield is 4.5%.

About Shin Nippon Biomedical Laboratories Ltd

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies.

Frequently asked questions

Is Shin Nippon Biomedical Laboratories Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Shin Nippon Biomedical Laboratories Ltd as 19.4% undervalued.

What is Shin Nippon Biomedical Laboratories Ltd's market cap?

Shin Nippon Biomedical Laboratories Ltd's market capitalization is EUR 253.95M.

What is Shin Nippon Biomedical Laboratories Ltd's P/E ratio?

Shin Nippon Biomedical Laboratories Ltd's price-to-earnings (P/E) ratio is 10.2.

Does Shin Nippon Biomedical Laboratories Ltd pay a dividend?

Shin Nippon Biomedical Laboratories Ltd has a dividend yield of 4.5%.

What does Shin Nippon Biomedical Laboratories Ltd do?

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally.